Abstract:Retinitis pigmentosa (RP) is the most genetically and phenotypically heterogeneous disorder, characterized by the progressive death of photoreceptor cells. In recent years, huge advances have been made in understanding the disease mechanisms, identifying causal genes, and developing therapeutic strategies for this disorder. This special issue updates the knowledge of RP and presents original clinical and experimental research. Photoreceptor cell death is known to be characterized at the early stage by caspase dependent or independent apoptosis and at late stage by necrosis, but the molecular mechanisms are not fully understood. In this special issue, S. R. Patnaik et al. review the functional role of RPGR protein complex in the pathogenesis of RP. Disease mechanisms are further elucidated in mouse (Q. Zheng et al.) and zebrafish models (Y. Liu et al. and S. Akhtar et al.). R. Migliorini et al. discuss RP associated syndromes, such as impaired ocular motility. E. Strobbe et al. report a correlation between ocular inflammation and endothelin (ET-1) plasma levels in early RP patients and suggest that anti-inflammatory therapy may slow the progression of RP. With the development of new technologies such as next generation sequencing (NGS), more and more mutant genes that cause retinal degenerative diseases have been found. B. Gong et al. reported here a recessive RDH12 mutation identified by exome sequencing in severe early onset RP patients, which further verifies the application of NGS for molecular diagnosis of RP. Meanwhile, many naturally occurring or genetically engineered animal models have shown gene mutations and phenotypes similar to human inherited retinal diseases, which has led to the development of a variety of therapeutic strategies for those inherited diseases regarded traditionally as incurable. Following the success of Leber congenital amaurosis 2 (LCA2) gene therapy clinical trials, more and more vector based gene therapy clinical trials have been performed on a variety of retinal conditions including RP with MERTK mutation. AAV-mediated gene replacement therapy shows great potential to treat patients in the early stage of the disease. Gene replacement therapy combined with other approaches like treatment with histone deacetylases inhibitors (reviewed by H. Zhang et al.) or antiapoptotic/inflammatory chemicals or natural products, which can extend the therapeutic window in middle to late stages of those patients, is a potentially promising strategy for improving photoreceptor function and significantly slowing the process of retinal degeneration. Cell replacement is a promising therapeutic strategy for RP. Successful cell replacement treatments have been done in RP animal models, providing hope for RP patients and their families. Chinese medicine has a long history in the treatment of RP; combinational treatment of Chinese medicine with Western medicine may further reduce the progression of RP (reviewed by J. Xu and Q. Peng). Xinhua Shu Ji-jing Pang Houbin Zhang David Mansfield

A New Study Progress of Molecular Genetics in Autosomal Dominant Retinitis Pigmentosa

Update on the Molecular Genetics of Retinitis Pigmentosa

Progress in Research on Pathogenic Genes of Retinitis Pigmentosa

Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies

Clinical and Genetic Identification of a Large Chinese Family with Autosomal Dominant Retinitis Pigmentosa

Targeted Next Generation Sequencing Revealed Novel PRPF31 Mutations in Autosomal Dominant Retinitis Pigmentosa

Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario

Clinical Features of Autosomal Dominant Retinitis Pigmentosa Associated with a Rhodopsin Mutation.

Systematic Evaluation Of A Targeted Gene Capture Sequencing Panel For Molecular Diagnosis Of Retinitis Pigmentosa

Variant Profiling of a Large Cohort of 138 Chinese Families With Autosomal Dominant Retinitis Pigmentosa

The Retinitis Pigmentosa Genes

Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis.

Retinitis Pigmentosa: Disease Mechanisms, Diagnosis, and Therapies

Targeted next generation sequencing identified novel mutations in RPGRIP1 associated with both retinitis pigmentosa and Leber's congenital amaurosis in unrelated Chinese patients.

Research progress in classification of retinitis pigmentosa

Next Generation Sequencing-Based Molecular Diagnosis of Retinitis Pigmentosa: Identification of a Novel Genotype-Phenotype Correlation and Clinical Refinements

Retinitis Pigmentosa: Progress and Perspective

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress

[Splicing Site Mutation of D19S418 in PRPF-31 Gene and Its Phenotypic Characters with Autosomal Dominant Retinitis Pigmentosa].

Targeted Next-Generation Sequencing Reveals Novel RP1 Mutations in Autosomal Recessive Retinitis Pigmentosa.

Retinitis pigmentosa associated rhodopsin gene mutants